Improving treatment for deadly brain tumors
Study finds ChemoID platform-predicted treatments lead to longer survival
New multi-institutional phase 3 clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma, a deadly brain tumor.
The University of Cincinnati’s Soma Sengupta, MD, PhD, a co-first author of the research and a University of Cincinnati Cancer Center physician-researcher, said the research focused on patients whose glioblastoma had returned after initial treatment.
The trial tested the effectiveness of a platform called ChemoID, a CLIA and CAP-accredited diagnostic test, developed by Dr. Pier Paolo Claudio and Dr. Jagan Valluri of Cordgenics LLC.
“ChemoID looks at cancer stem cells and their sensitivity to specified drugs to see which ones will work in a given cancer setting,” said Sengupta, UC associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist, funded by the Harold C. Schott Endowed Chair in Molecular Therapeutics (Neurosurgery) and the Pam and Tom Mischell Funds.
Soma Sengupta, MD, PhD. Photo/UC Health.
Patients in the trial were randomized to have the choice of chemotherapy treatment decided through ChemoID or to have physicians choose the chemotherapy using standard methods. Sengupta noted oncologists choosing treatments are often dictated by guidelines and insurance considerations.
Those who had their treatments selected through ChemoID had a significantly lower risk of death and, on average, survived 3.5 months longer than those in the physician-choice group.
“We were pleasantly surprised that the ChemoID group did better and that a cancer stem cell-derived test is important in this disease,” Sengupta said. “Where survival in recurrent glioblastoma is extremely poor, 3.5 months or more is wonderful. Some of my patients on this trial are still alive.”
Claudio explained that because ChemoID focuses on choosing treatments using commercially available chemotherapies, this approach offers a way for patients to receive more effective treatment at a lower cost.
Sengupta said the team plans to apply for funding through the National Institutes of Health to develop ChemoID further. A modified platform could expand to include immunotherapy treatments or targeted therapies.
According to Valluri, if the anti-cancer therapy that targets cancer stem cells is incorporated earlier in the treatment plan, ineffective treatments will be eliminated, and patients will be able to receive the maximum therapeutic benefit.
“This is an example of a highly collaborative project,” Sengupta said. “At UC alone, several colleagues, including Dr. Mario Zuccarello and Dr. Rekha Chaudhary, were involved.”
Featured photo at top of a CT brain scan. Photo/Tonpor Kasa/iStock.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
Three years, countless stories
May 15, 2026
UC's Klekamp Law celebrates its 193rd Hooding with stories from graduates reflecting on their paths through the college.
Driven by curiosity, guided by care
May 14, 2026
Max Wilson, a University of Cincinnati College of Allied Health Sciences health sciences major on the pre-physician assistant track, found his path expanding beyond the classroom and into hands-on research focused on human performance and patient care.
New cohort of nursing students get ready to join co-ops
May 14, 2026
A new chapter is beginning for more than 100 University of Cincinnati College of Nursing rising seniors as they embark on one of the most distinctive experiences in undergraduate nursing education: the UC Nursing Co-op Program. The incoming cohort will fan out across Cincinnati's premier healthcare institutions, stepping into some of the most dynamic and specialized clinical environments in the region. Placement sites include UC Medical Center (UCMC), West Chester Hospital, Cincinnati Children's Hospital Medical Center (CCHMC) Burnet, College Hill, and Liberty campus.